Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 9/20 | 1.00 |
| ▸ | ATIC | P31939 | 4/20 | 0.71 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.60 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.58 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lometrexol SCHEMBL17520098 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL10067961 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL14365 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL18530 | 0.88 | GART (0.78) | GARTATIC | |
| SCHEMBL10512772 | 0.87 | GART (0.78) | GARTATICSOSTMTHFD1 | |
| SCHEMBL10512730 | 0.87 | GART (0.78) | GARTATICSOSTMTHFD1 | |
| Lometrexol SCHEMBL29356838 | 0.87 | GART (0.77) | GARTATICSOST | |
| Lometrexol SCHEMBL21248426 | 0.87 | GART (0.77) | GARTATIC | |
| SCHEMBL9837105 | 0.87 | GART (0.77) | GARTATICSOSTMTHFD2MTHFD1 | |
| SCHEMBL9536119 | 0.87 | GART (0.77) | GARTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167377-A1 | Inhibitors of glycinamide ribonucleotide transformylase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-19 | — | — | US | disclosed |
| WO-2007023243-A2 | CLEAVAGE OF ANTIFOLATE COMPOUNDS | PROTHERICS MEDICINES DEVELOPMENT LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167377-A1 | Inhibitors of glycinamide ribonucleotide transformylase | TYMS, NMT2, NMT1 | GART 5/4885ATIC 288/4885SOST 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.